🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

206+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 206 recruiting trials for “t-cell-prolymphocytic-leukemia

Phase 1RecruitingNCT05602363

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

🏥 Carna Biosciences, Inc.📍 13 sites📅 Started Aug 2023View details ↗
Phase 2RecruitingNCT05672355

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

👨‍⚕️ Alexey V Danilov, City of Hope Medical Center📍 1 site📅 Started Aug 2023View details ↗
Phase 2RecruitingNCT05873712

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

👨‍⚕️ Jennifer A Woyach, MD, Ohio State University Comprehensive Cancer Center📍 3 sites📅 Started Jul 2023View details ↗
RecruitingNCT05978141

A Registry for People With T-cell Lymphoma

👨‍⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 26 sites📅 Started Jul 2023View details ↗
Phase 2RecruitingNCT06061094

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

👨‍⚕️ Nicola Goekbuget, MD, Department of Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany📍 85 sites📅 Started Jul 2023View details ↗
RecruitingNCT06203652

The Pathogenesis and Prognostic Factors of Lymphoma

🏥 Shanghai Zhongshan Hospital📍 1 site📅 Started Jun 2023View details ↗
Phase 2RecruitingNCT04941716

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

👨‍⚕️ Mazyar Shadman, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started May 2023View details ↗
Phase 2RecruitingNCT05289687

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

👨‍⚕️ Shira Dinner, MD, Northwestern University📍 1 site📅 Started May 2023View details ↗
Phase 1RecruitingNCT06593145

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

👨‍⚕️ Emilian Snarski, FamiCordTx S.A.📍 2 sites📅 Started May 2023View details ↗
Phase 1RecruitingNCT04972942

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma

👨‍⚕️ Mitchell Cairo, MD, New York Medical College📍 16 sites📅 Started May 2023View details ↗
Phase 2RecruitingNCT05748171

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

👨‍⚕️ Pfizer CT.gov Call Center, Pfizer📍 76 sites📅 Started May 2023View details ↗
RecruitingNCT06334835

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.

👨‍⚕️ Giovanni Smaldone, PhD, IRCCS SYNLAB SDN📍 1 site📅 Started Apr 2023View details ↗
Phase 2RecruitingNCT05453500

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

👨‍⚕️ Ryan D. Cassaday, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2023View details ↗
Phase 1, PHASE2RecruitingNCT05310591

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

🏥 Assistance Publique - Hôpitaux de Paris📍 13 sites📅 Started Mar 2023View details ↗
Phase 1RecruitingNCT05705570

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

👨‍⚕️ Nelson Hamerschlak, MD, PhH, Hospital Israelita Albert Einstein📍 1 site📅 Started Feb 2023View details ↗
Phase 1RecruitingNCT05679895

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

🏥 OneChain Immunotherapeutics📍 2 sites📅 Started Jan 2023View details ↗
Phase 1, PHASE2RecruitingNCT05674175

Co-administration of CART22-65s and huCART19 for B-ALL

👨‍⚕️ Regina Myers, MD, Children's Hospital of Philadelphia📍 1 site📅 Started Jan 2023View details ↗
Phase 1RecruitingNCT03633955

Pilot Imaging Study of Leukemia

👨‍⚕️ Jennifer Holter, MD, Stephenson Cancer Center📍 3 sites📅 Started Jan 2023View details ↗
Phase 2RecruitingNCT05388006

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

👨‍⚕️ Paul J. Hampel, MD, Mayo Clinic in Rochester📍 3 sites📅 Started Jan 2023View details ↗
Phase 2RecruitingNCT05536349

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

👨‍⚕️ Nitin Jain, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Dec 2022View details ↗
← PreviousPage 7 of 11Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →